Ameriprise

Ameriprise’s RAPT Therapeutics RAPT Stock Holding History

Ameriprise’s Portfolio RAPT Stock Details RAPT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-51,406	Closed	-$1.33M	–	4193
2025 Q3	$1.33M	Buy	+51,406	New	+$673K	﹤0.01%	3219

Other funds holding RAPT

Medicxi Ventures Management St. Helier, Jersey $982M AUM 210.17% 1-Year Est. Return

TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return

FCPM III Services Naarden, Netherlands $722M AUM 73.61% 1-Year Est. Return

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

Foresite Capital Management VI Larkspur, California $460M AUM 261.77% 1-Year Est. Return

Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return

Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return

Ameriprise's RAPT Position: Q4 2025 in Review

Ameriprise sold out of RAPT Therapeutics (RAPT) in Q4 2025, closing a stake of 51,406 shares — an estimated $1.33M sold.

Ameriprise first reported a position in RAPT in Q3 2025 and held it in 1 quarter. The position peaked at $1.33M in Q3 2025. 105 funds tracked by Wall St. Rank hold RAPT as of Q4 2025.

Ameriprise reported no remaining RAPT Therapeutics position as of Q4 2025 after selling out during the quarter.
Ameriprise sold 51,406 RAPT Therapeutics shares in Q4 2025, an estimated $1.33M.
Ameriprise first reported a position in RAPT Therapeutics in Q3 2025 and held it in 1 quarter.
Ameriprise's RAPT Therapeutics position peaked at $1.33M in Q3 2025.
105 funds tracked by Wall St. Rank held RAPT Therapeutics as of Q4 2025.

Based on Ameriprise's 13F filing for Q4 2025, filed 17 Feb 2026.